MAbSilico is the best combination of computational scientists and biologists. Our AI-based technologies are validated and improved in the wet-lab to generate solutions that are applicable to any target, with no re-training required. The team gathers more than 100 scientific publications, and 4 patents. Our scientific and advisory board englobes KOLs and entrepreneurs sharing our vision to change antibody design and discovery.
MAbSilico originates from the synergy between AI and biology experts who learned along the years how to speak the same language
MAbSilico's task force seizes the full pipeline, from biological data generation, to AI solutions building, and final embedding into a software platform.
Anne holds a PhD in Biomathematics. She's been working on protein-protein interactions at CNRS for more than 20 years.
Astrid holds a PhD in cellular biology. She worked on GPCRs mechanisms of action and their modulation by antibodies.
Vincent holds a PhD in biology and worked in biotech and public research institutes in Europe before founding MAbSilico.
Thomas holds a PhD in structural biology and computer sciences. He worked on implementing AI approaches in genomics, docking, immuno-oncology.
Gathers experts in immunology, biotech and pharma industry helping MAbSilico grow and provide solutions adapted to the field.
Experts in immunology, biotech and pharma industry helping MAbSilico grow and provide solutions adapted to the field.
Send us an email.
Our collaborators share clear vision and a desire to make a difference in drug discovery.
Other collaborators helping MAbSilico to go further:
Our partners share our vision to use computation to accelerate, succeed faster and bring better drug for patients.
Other collaborators helping MAbSilico to go faster:
MAbSilico has the desire to bring our computational designed antibodies to best scientists and help them solving cutting edge research project.
Universities and institute powered by MAbSilico
Private companies and governmental agencies are helping MAbSilico to accelerate the revolution for AI-based antibody discovery.
Our biologists have access to state-of-the-art technologies to validate binding interactions of antibodies to their antigen. MAbSilico is working with 3rd party for antibody production and we can adapt to fulfill your requirements. Our biologists have extensive experience in GPCR, immunology and antibody discovery.
Based on existing data and solutions such as Alphafold, MAbSilico's experts can design by structural homology modeling the 3D template of your target. To anticipate structural modification due to biological context, MAbSilico can model different conformations of your target.
The first information is the target name and its UNIPROT number. These are the only information for antibody de novo design. After an analysis by our structural experts, we can estimate if our technology can be applied to accelerate and increase the success of your project.
If you have already selected antibodies, we need their sequences for the characterization or their optimization.
Drop us a line if you want to know more about our technology or if you are willing to talk about your projects. We are always keen on discussing science!
.png){kind=logo}
